Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 11.64% is 39% above its 5-year average of 8.38%, around the middle of its 5-year range (0.65%–17.90%).
As of the fiscal period ended Tuesday, June 30, 2026. 63.98% above its 12-month average of 7.10%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 11.64%.
DEBT TO ASSETS RATIO
11.64%
DEBT TO ASSETS RATIO AVG TTM
7.10%
DEBT TO ASSETS RATIO AVG 3Y
10.77%
DEBT TO ASSETS RATIO AVG 5Y
8.38%
DEBT TO ASSETS RATIO AVG 10Y
13.88%
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+63.98%
CURRENT VS 3Y AVG
+8.08%
CURRENT VS 5Y AVG
+38.95%
CURRENT VS 10Y AVG
-16.12%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
+12832.24%
vs the sector median at left
Profound Medical Corp.
Market Cap
$223.48M
Debt to Assets Ratio
11.64%
TTM Avg
7.10%
3Y Avg
10.77%
5Y Avg
8.38%
Market Cap
$223.45M
Debt to Assets Ratio
0.05%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$216.82M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$214.64M
Debt to Assets Ratio
0.02%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$214.41M
Debt to Assets Ratio
0.12%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$232.88M
Debt to Assets Ratio
0.17%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Profound Medical Corp. (PROF) | $223.48M | 11.64% | 7.10% | 10.77% | 8.38% |
| Keros Therapeutics, Inc. (KROS)vs › | $223.45M | 0.05% | N/A | N/A | N/A |
| Biodesix, Inc. (BDSX)vs › | $228.74M | 0.75% | N/A | N/A | N/A |
| Vogenx Inc. (VOGX)vs › | $229.03M | N/A | N/A | N/A | N/A |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $216.82M | 0.00% | N/A | N/A | N/A |
| MacroGenics, Inc. (MGNX)vs › | $232.01M | 0.10% | N/A | N/A | N/A |
| Niagen Bioscience Inc (NAGE)vs › | $214.64M | 0.02% | N/A | N/A | N/A |
| Lyell Immunopharma, Inc. (LYEL)vs › | $214.41M | 0.12% | N/A | N/A | N/A |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $232.88M | 0.17% | N/A | N/A | N/A |
| SIGA Technologies, Inc. (SIGA)vs › | $234.62M | 0.00% | N/A | N/A | N/A |
Debt/Assets
11.6%
Debt/Equity
0.15
Current Ratio
6.45
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 11.64% |
| 2026-03-31 | 10.16% |
| 2025-12-31 | 3.34% |
| 2025-09-30 | 0.65% |
| 2025-06-30 | 9.69% |
| 2025-03-31 | 8.02% |
| 2024-12-31 | 7.29% |
| 2024-09-30 | 14.75% |
| 2024-06-30 | 13.30% |
| 2024-03-31 | 12.56% |
| 2023-12-31 | 17.90% |
| 2023-09-30 | 16.11% |
| 2023-06-30 | 14.59% |
| 2023-03-31 | 13.30% |
| 2022-12-31 | 12.78% |
| 2022-09-30 | 1.69% |
| 2022-06-30 | 1.69% |
| 2022-03-31 | 1.66% |
| 2021-12-31 | 1.59% |
| 2021-09-30 | 1.55% |
| 2021-06-30 | 1.64% |
| 2021-03-31 | 1.62% |
| 2020-12-31 | 1.60% |
| 2020-09-30 | 1.69% |
| 2020-06-30 | 2.97% |
| 2020-03-31 | 2.83% |
| 2019-12-31 | 36.50% |
| 2019-09-30 | 33.85% |
| 2019-06-30 | 38.31% |
| 2019-03-31 | 32.19% |
| 2018-12-31 | 18.92% |
| 2018-09-30 | 23.70% |
| 2018-06-30 | 8.07% |
| 2018-03-31 | 5.67% |
| 2017-12-31 | 18.45% |
| 2017-09-30 | 17.11% |
| 2017-06-30 | 33.03% |
| 2017-03-31 | 33.30% |
| 2016-12-31 | 28.02% |
| 2016-09-30 | 52.83% |
| 2016-06-30 | 41.31% |
| 2016-03-31 | 32.63% |
| 2015-12-31 | 27.60% |
| 2015-09-30 | 23.15% |
| 2015-06-30 | 19.92% |
| 2015-03-31 | 1191.03% |
| 2014-12-31 | 0.00% |
| 2014-09-30 | 0.00% |
